Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons.

ABSTRACT:

Introduction

Adult dermatomyositis (DM) and juvenile dermatomyositis (JDM) are rare autoimmune diseases with characteristic skin rashes, weakness, and other systemic features. Upregulated interferon signaling has been consistently described in both adult and juvenile DM which makes janus kinase inhibitors (jakinibs) an attractive therapeutic agent that has a targeted mechanism of action.

Areas covered

Herein is a review of the growing literature of jakinib use in adult and juvenile DM, including reports on specific disease features and safety of jakinibs in this population and a comparison between adult and juvenile DM. We performed a literature review using PubMed including all English-language publications before 1 February 2024 and abstracts from key recent rheumatology c

SUBMITTER: Wallwork RS 

PROVIDER: S-EPMC12185052 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature